BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nast A, Smith C, Spuls P, Avila Valle G, Bata‐csörgö Z, Boonen H, De Jong E, Garcia‐doval I, Gisondi P, Kaur‐knudsen D, Mahil S, Mälkönen T, Maul J, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt K, Sator P, Schmitt‐egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021;35:281-317. [DOI: 10.1111/jdv.16926] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 30.0] [Reference Citation Analysis]
Number Citing Articles
1 Rusiñol L, Camiña-conforto G, Puig L. Biologic treatment of psoriasis in oncologic patients. Expert Opinion on Biological Therapy 2022. [DOI: 10.1080/14712598.2022.2152322] [Reference Citation Analysis]
2 Di Cesare A, Ricceri F, Rosi E, Fastame MT, Prignano F. Therapy of PsO in Special Subsets of Patients. Biomedicines 2022;10:2879. [DOI: 10.3390/biomedicines10112879] [Reference Citation Analysis]
3 Pellegrini C, Esposito M, Rossi E, Gisondi P, Piaserico S, Dapavo P, Conti A, Gambardella A, Burlando M, Narcisi A, Offidani A, Balestri R, Bardazzi F, Prignano F, Mugheddu C, Romanelli M, Malara G, Schinzari G, Fargnoli MC. Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study. Dermatol Ther (Heidelb) 2022. [PMID: 36169883 DOI: 10.1007/s13555-022-00797-9] [Reference Citation Analysis]
4 Bakulev AL, Kruglova LS. Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab. Vestnik dermatologii i venerologii 2022;98:23-30. [DOI: 10.25208/vdv1349] [Reference Citation Analysis]
5 Bachelez H, Barker J, Burden AD, Navarini AA, Krueger JG. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. Expert Rev Clin Immunol 2022. [PMID: 36062811 DOI: 10.1080/1744666X.2022.2116003] [Reference Citation Analysis]
6 Boehncke WH, Brembilla NC. Pathogenesis-oriented therapy of psoriasis using biologics. Expert Opin Biol Ther 2022. [PMID: 35815360 DOI: 10.1080/14712598.2022.2100219] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Carrascosa J, Puig L, Romero I, Salgado-boquete L, del Alcázar E, Lencina J, Moreno D, de la Cueva P. Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 2 «Manejo de poblaciones especiales, pacientes con comorbilidad y gestión del riesgo». Actas Dermo-Sifiliográficas 2022;113:583-609. [DOI: 10.1016/j.ad.2022.01.024] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Guillet C, Seeli C, Nina M, Maul LV, Maul JT. The impact of gender and sex in psoriasis: What to be aware of when treating women with psoriasis. Int J Womens Dermatol 2022;8:e010. [PMID: 35619672 DOI: 10.1097/JW9.0000000000000010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Carrascosa JM, Puig L, Romero IB, Salgado-Boquete L, Del Alcázar E, Lencina JJA, Moreno D, de la Cueva P. [Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2-Management of Special Populations, Patients With Comorbid Conditions, and Risk. Actas Dermosifiliogr 2022;113:T583-609. [PMID: 35748004 DOI: 10.1016/j.ad.2022.01.040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Johansen CB, Egeberg A, Jimenez-solem E, Skov L, Thomsen SF. Psoriasis and adverse pregnancy outcomes: A nationwide case-control study in 491,274 women in Denmark. JAAD International 2022;7:146-55. [DOI: 10.1016/j.jdin.2022.03.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Megna M, Patruno C, Bongiorno MR, Gambardella A, Guarneri C, Romita P, Raimondo A, Loconsole F, Fabbrocini G. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection. Clin Drug Investig 2022. [PMID: 35633470 DOI: 10.1007/s40261-022-01163-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Balakirski G, Gerdes S, Beissert S, Ochsendorf F, von Kiedrowski R, Wilsmann-Theis D. Psoriasis-Therapie während Schwangerschaft und Stillzeit. J Dtsch Dermatol Ges 2022;20:653-85. [PMID: 35578434 DOI: 10.1111/ddg.14789_g] [Reference Citation Analysis]
13 Balakirski G, Gerdes S, Beissert S, Ochsendorf F, von Kiedrowski R, Wilsmann-Theis D. Therapy of psoriasis during pregnancy and breast-feeding. J Dtsch Dermatol Ges 2022;20:653-83. [PMID: 35578438 DOI: 10.1111/ddg.14789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yiu ZZN, Chi CC, Ingram JR, Flohr C. Checking for update…living systematic reviews and clinical practice guidelines in the BJD. Br J Dermatol 2022;186:761-2. [PMID: 35501944 DOI: 10.1111/bjd.20896] [Reference Citation Analysis]
15 Megna M, Patruno C, Bongiorno MR, Gambardella A, Guarneri C, Foti C, Lembo S, Loconsole F, Fabbrocini G. Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection. J Dermatolog Treat 2022;:1-19. [PMID: 35385362 DOI: 10.1080/09546634.2022.2062280] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Carrascosa J, Puig L, Belinchón Romero I, Salgado-boquete L, del Alcázar E, Andrés Lencina J, Moreno D, de la Cueva P. [Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy. Actas Dermo-Sifiliográficas 2022;113:T261-T277. [DOI: 10.1016/j.ad.2021.10.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Carrascosa J, Puig L, Belinchón Romero I, Salgado-boquete L, del Alcázar E, Andrés Lencina J, Moreno D, de la Cueva P. Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 1. «Conceptos y manejo general de la psoriasis con terapia biológica». Actas Dermo-Sifiliográficas 2022;113:261-277. [DOI: 10.1016/j.ad.2021.10.003] [Reference Citation Analysis]
18 Esposito M, Campanati A, Giunta A, Calianno G, Bianchi L, Diotallevi F, Offidani AM, Fargnoli MC. Dimethyl Fumarate's Effectiveness and Safety in Psoriasis: A Real-Life Experience During the COVID-19 Pandemic. Dermatol Ther (Heidelb) 2022. [PMID: 35103934 DOI: 10.1007/s13555-022-00684-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Kougkas N, Kruger-krasagakis S, Papadaki E, Mastorodemos V. Successful treatment of highly active multiple sclerosis and psoriasis exacerbation with natalizumab and secukinumab combination. A case report and literature review. Neuroimmunology Reports 2022;2:100054. [DOI: 10.1016/j.nerep.2022.100054] [Reference Citation Analysis]
20 Ring J. Dermatology and venereology - highlights in research and patient care in 2021. J Eur Acad Dermatol Venereol 2022;36:8-10. [PMID: 34897828 DOI: 10.1111/jdv.17822] [Reference Citation Analysis]
21 Mahé E. Gestion à long terme du psoriasis par les biothérapies. Annales de Dermatologie et de Vénéréologie - FMC 2021;1:5S13-5S21. [DOI: 10.1016/s2667-0623(21)00898-9] [Reference Citation Analysis]
22 Mastorino L, Dapavo P, Avallone G, Merli M, Cariti C, Rubatto M, Pala V, Quaglino P, Ribero S. Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden? J Dermatolog Treat 2021;:1-8. [PMID: 34409918 DOI: 10.1080/09546634.2021.1970706] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Barenbrug L, Groen MT, Hoentjen F, van Drongelen J, Reek JMPAVD, Joosten I, de Jong EMGJ, van der Molen RG. Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-α during pregnancy: A systemic review and meta-analysis. J Autoimmun 2021;122:102676. [PMID: 34126302 DOI: 10.1016/j.jaut.2021.102676] [Reference Citation Analysis]
24 Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond) 2021;21:170-3. [PMID: 34001566 DOI: 10.7861/clinmed.2021-0257] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 18.0] [Reference Citation Analysis]